Cargando…

Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder

Objectives: To investigate child and parental characteristics of medication use for attention-deficit/hyperactivity disorder (ADHD). Methods: Participants were part of the prospective population-based Norwegian Mother, Father and Child Cohort study (MoBa) (n = 114,500 children, 95,000 mothers, and 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Oerbeck, Beate, Furu, Kari, Zeiner, Pal, Aase, Heidi, Reichborn-Kjennerud, Ted, Pripp, Are Hugo, Overgaard, Kristin Romvig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475088/
https://www.ncbi.nlm.nih.gov/pubmed/32672488
http://dx.doi.org/10.1089/cap.2019.0019
_version_ 1783579448817221632
author Oerbeck, Beate
Furu, Kari
Zeiner, Pal
Aase, Heidi
Reichborn-Kjennerud, Ted
Pripp, Are Hugo
Overgaard, Kristin Romvig
author_facet Oerbeck, Beate
Furu, Kari
Zeiner, Pal
Aase, Heidi
Reichborn-Kjennerud, Ted
Pripp, Are Hugo
Overgaard, Kristin Romvig
author_sort Oerbeck, Beate
collection PubMed
description Objectives: To investigate child and parental characteristics of medication use for attention-deficit/hyperactivity disorder (ADHD). Methods: Participants were part of the prospective population-based Norwegian Mother, Father and Child Cohort study (MoBa) (n = 114,500 children, 95,000 mothers, and 75,000 fathers). This cohort was linked to the Norwegian Prescription Database (NorPD) and the Norwegian Patient Registry (NPR) to compare child and parental characteristics in children medicated and not medicated for ADHD during years 2008–2013. Results: One thousand seven hundred and sixty-four children (74% boys) with ADHD (International Classification of Diseases [ICD-10]: F90 and F98.8) were identified. One thousand three hundred and sixty-two (77%) used medication. Boys and girls did not differ in the use of ADHD medication (both 77%). Mean age at first prescription was 9 years in both boys and girls, and age at ADHD diagnosis was 8 years in medicated and unmedicated children. Significantly more hyperkinetic conduct disorders (F90.1), and significantly fewer with attention-deficit disorder (F98.8) were found among the medicated children compared to the unmedicated children. The medicated children also had a significantly lower global functioning (Child Global Assessment Scale). Child disruptive symptoms reported in the MoBa child age 3 year questionnaire were significantly higher in children who used medication compared to the nonusers (t = 2.2, p = 0.03), and group differences in ADHD symptoms at age 3 years were close to significant (t = 1.8, p = 0.07). Other preschool child and parental characteristics were not significantly different in the two groups. Conclusion: In this large birth cohort study, where a great majority of children with ADHD used medication, only child characteristics were significantly associated with the use of medication. We could not replicate previous findings suggesting that “environmental factors,” such as parental education and psychopathology, drive medication use. The small differences between medicated and unmedicated children in this cohort study, where a majority used medication, might be due to strong established clinical practices where medication is offered as a treatment option, particularly for hyperkinetic conduct disorder in an egalitarian high-income society.
format Online
Article
Text
id pubmed-7475088
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-74750882020-09-08 Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder Oerbeck, Beate Furu, Kari Zeiner, Pal Aase, Heidi Reichborn-Kjennerud, Ted Pripp, Are Hugo Overgaard, Kristin Romvig J Child Adolesc Psychopharmacol Original Articles Objectives: To investigate child and parental characteristics of medication use for attention-deficit/hyperactivity disorder (ADHD). Methods: Participants were part of the prospective population-based Norwegian Mother, Father and Child Cohort study (MoBa) (n = 114,500 children, 95,000 mothers, and 75,000 fathers). This cohort was linked to the Norwegian Prescription Database (NorPD) and the Norwegian Patient Registry (NPR) to compare child and parental characteristics in children medicated and not medicated for ADHD during years 2008–2013. Results: One thousand seven hundred and sixty-four children (74% boys) with ADHD (International Classification of Diseases [ICD-10]: F90 and F98.8) were identified. One thousand three hundred and sixty-two (77%) used medication. Boys and girls did not differ in the use of ADHD medication (both 77%). Mean age at first prescription was 9 years in both boys and girls, and age at ADHD diagnosis was 8 years in medicated and unmedicated children. Significantly more hyperkinetic conduct disorders (F90.1), and significantly fewer with attention-deficit disorder (F98.8) were found among the medicated children compared to the unmedicated children. The medicated children also had a significantly lower global functioning (Child Global Assessment Scale). Child disruptive symptoms reported in the MoBa child age 3 year questionnaire were significantly higher in children who used medication compared to the nonusers (t = 2.2, p = 0.03), and group differences in ADHD symptoms at age 3 years were close to significant (t = 1.8, p = 0.07). Other preschool child and parental characteristics were not significantly different in the two groups. Conclusion: In this large birth cohort study, where a great majority of children with ADHD used medication, only child characteristics were significantly associated with the use of medication. We could not replicate previous findings suggesting that “environmental factors,” such as parental education and psychopathology, drive medication use. The small differences between medicated and unmedicated children in this cohort study, where a majority used medication, might be due to strong established clinical practices where medication is offered as a treatment option, particularly for hyperkinetic conduct disorder in an egalitarian high-income society. Mary Ann Liebert, Inc., publishers 2020-09-01 2020-08-28 /pmc/articles/PMC7475088/ /pubmed/32672488 http://dx.doi.org/10.1089/cap.2019.0019 Text en © Beate Oerbeck et al. 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
spellingShingle Original Articles
Oerbeck, Beate
Furu, Kari
Zeiner, Pal
Aase, Heidi
Reichborn-Kjennerud, Ted
Pripp, Are Hugo
Overgaard, Kristin Romvig
Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
title Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
title_full Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
title_fullStr Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
title_full_unstemmed Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
title_short Child and Parental Characteristics of Medication Use for Attention-Deficit/Hyperactivity Disorder
title_sort child and parental characteristics of medication use for attention-deficit/hyperactivity disorder
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475088/
https://www.ncbi.nlm.nih.gov/pubmed/32672488
http://dx.doi.org/10.1089/cap.2019.0019
work_keys_str_mv AT oerbeckbeate childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder
AT furukari childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder
AT zeinerpal childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder
AT aaseheidi childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder
AT reichbornkjennerudted childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder
AT pripparehugo childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder
AT overgaardkristinromvig childandparentalcharacteristicsofmedicationuseforattentiondeficithyperactivitydisorder